Juvenescence Ltd. Files 31st Amendment to AgeX Therapeutics Stake

TL;DR

**Juvenescence keeps tweaking its AgeX stake, signaling potential ongoing strategic shifts.**

AI Summary

Juvenescence Limited, a major shareholder in AgeX Therapeutics, Inc., filed an Amendment No. 31 to its Schedule 13D on February 1, 2024. This filing updates their beneficial ownership of AgeX Therapeutics' Common Stock, par value $0.0001 per share. While the filing itself doesn't detail specific transactions, the frequent amendments (31 total) suggest ongoing changes in Juvenescence's stake or their intentions regarding AgeX. This matters to investors because significant changes in ownership by a large institutional holder like Juvenescence can signal shifts in confidence or strategic direction for AgeX Therapeutics.

Why It Matters

Frequent amendments to a 13D filing by a major shareholder like Juvenescence Limited can indicate ongoing strategic shifts or changes in their investment thesis for AgeX Therapeutics, potentially impacting the stock's future direction.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the high number of amendments (31) suggests ongoing, potentially significant, changes in a major shareholder's position, which introduces uncertainty.

Analyst Insight

Investors should monitor future 13D/A filings from Juvenescence Limited for AgeX Therapeutics to understand any significant changes in their ownership percentage or stated intentions, as these could influence market perception and stock performance.

Key Numbers

• 31 — Amendment Number (This is the 31st amendment to the Schedule 13D filing by Juvenescence Limited, indicating numerous prior updates to their stake or intentions.)
• February 1, 2024 — Date of Event (This is the date of the event that triggered the requirement for this specific filing.)

Key Players & Entities

• Juvenescence Limited (company) — the reporting person and major shareholder of AgeX Therapeutics, Inc.
• AgeX Therapeutics, Inc. (company) — the subject company whose securities are being reported on
• David Gill (person) — contact person for Juvenescence Limited
• $0.0001 (dollar_amount) — par value per share of AgeX Therapeutics Common Stock

Forward-Looking Statements

• Juvenescence Limited will continue to actively manage its stake in AgeX Therapeutics, potentially leading to further amendments. (Juvenescence Limited) — high confidence, target: Within the next 6-12 months

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $500,000 — Issuer each in the principal amount of $500,000. On February 1, 2024, the 211,600 outs

Filing Documents

• tm242510d3_sc13da.htm (SC 13D/A) — 42KB
• 0001104659-24-010355.txt ( ) — 44KB

of the Original Statement is hereby amended and restated in

Item 5 of the Original Statement is hereby amended and restated in its entirety to read as follows: (a)The Reporting Persons beneficially owns an aggregate of 89,308,271 shares of Common Stock, representing (i) 66,447,499 shares of Common Stock held directly by JuvVentures (UK) Limited, (ii) 308,565 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility (as defined below), (iii) 10,357,086 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note (as defined below) and (iv) 12,195,121 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on January 31, 2024 . This aggregate amount represents approximately 80.6% of the Issuer’s outstanding common stock, based upon 37,951,261 shares outstanding as of November 6, 2023, as reported on the Issuer’s Annual Report filed on Form 10-Q on November 14, 2023, and giving effect to the exercise of the Warrants, conversion of amounts outstanding under the A&R Secured Note and conversion of the outstanding shares of the Series A Preferred Stock and Series B Preferred Stock. (b)The information in Items 7 through 10 of each cover page is incorporated by reference into this Item 5(b). (c)Except for the information set forth in Item 6, which is incorporated by reference into this Item 5(c), the Reporting Persons have effected no transactions relating to the Common Stock during the past 60 days. (d)- (e)Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

of the Original Statement is hereby supplemented as follows

Item 6 of the Original Statement is hereby supplemented as follows: On February 1, 2024, the Reporting Person funded additional advances to the Issuer each in the principal amount of $500,000. On February 1, 2024, the 211,600 outstanding shares of Series A Preferred Stock held by JuvVentures (UK) Limited automatically converted into Common Stock and the 148,400 outstanding shares of Series B Preferred Stock held by JuvVentures (UK) Limited automatically converted into Common Stock.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct. Date: February 5, 2024 JUVENESCENCE LIMITED By: /s/ Gregory H. Bailey Name: Gregory H. Bailey Title: Executive Chairman Date: February 5, 2024 JuvVentures (UK) Limited By: /s/ David Gill Name: David Gill Title: Director

View Full Filing

View this SC 13D/A filing on SEC EDGAR